Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.09.022Source: DataRank Database

Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor is a research paper published in Journal of Cystic Fibrosis (2024). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

27 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 7.59)OA: closedTopics (51)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Hannah Smith ORCID,Sasan Mirfakhraee ORCID,Joan Reisch ORCID,Leah A. Cohen ORCID,Raksha Jain ORCID

Live enrichment

PubMed:39419654 OpenAlex:https://openalex.org/W4403461234

Cystic Fibrosis Foundation

National Institutes of Health

Sun Pharma

FWCI

7.59

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S1569199324017909?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199324017909?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2024.09.022

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39419654

Fields of Study

Cystic Fibrosis Research AdvancesAsthma and respiratory diseasesChronic Obstructive Pulmonary Disease (COPD) ResearchHumansCystic FibrosisMetabolic SyndromeMaleQuinolonesAminophenolsFemaleBenzodioxolesDrug CombinationsIndolesAdultProspective StudiesPyrrolesPyrazolesChloride Channel AgonistsPyridinesAdolescentQuinolines

MeSH Terms

AdolescentAdultAminophenolsCystic FibrosisDrug CombinationsFemaleHumansIndolesMaleProspective StudiesPyrazolesPyridinesPyrrolesPyrrolidinesQuinolinesQuinolonesMetabolic SyndromeBenzodioxolesYoung AdultChloride Channel Agonists

Keywords

IvacaftorCystic fibrosisMedicineInternal medicineCystic fibrosis transmembrane conductance regulatorHypertensionmetabolic syndromeDyslipidemiaBody-mass IndexElexacaftor-tezacaftor-ivacaftor

Sustainable Development Goals

SDG 0: Zero hunger

Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor

FAIR Checklist

Authors (7)

Funding (3 grants)

Impact

Open Access

Topics